

IAS 2019 Track categories

Track B – Clinical science

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

Course of HIV disease

- | | |
|----|-------------------------------------------------------------------------------------------|
| B1 | Acute and early infection |
| B2 | Impact of co-factors (e.g., viral clade, tropism, genetic factors) on disease progression |
| B3 | Long-term non-progressors and elite controllers |
| B4 | Morbidity, mortality and life expectancy in clinical research |
| B5 | Determinants of HIV progression |
| B6 | HIV-2 |

Diagnostic and monitoring tools

- | | |
|-----|-----------------------------------------------------------|
| B7 | HIV testing and retesting |
| B8 | Genotyping and viral tropism testing (viral and proviral) |
| B9 | CD4 measurement |
| B10 | Viral load measurement |
| B11 | ART adherence measurement |
| B12 | Drug resistance testing |
| B13 | Diagnostics of co-infections and co-morbidities |
| B14 | Markers for the prediction of disease progression |

Co-infections (including opportunistic infections)

- | | |
|-----|----------------------------------------------------|
| B15 | Opportunistic infections (excluding tuberculosis) |
| B16 | Tuberculosis and other mycobacteria |
| B17 | Viral hepatitis B and D |
| B18 | Viral hepatitis C |
| B19 | Other viral hepatitis (A and E) |
| B20 | Human T-lymphotropic virus type 1 (HTLV-1) |
| B21 | Human papillomavirus |
| B22 | Syphilis and other sexually transmitted infections |
| B23 | Other bacterial, viral and parasitic infections |

Co-morbidities and complications (including those related to ART)

- | | |
|-----|-------------------------------------------------|
| B24 | Neurologic disorders |
| B25 | Depression and other psychiatric manifestations |
| B26 | Malignancies (AIDS and non-AIDS) |
| B27 | Cardiovascular disease |

B28	Bone disease
B29	Renal disease
B30	Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy)
B31	Hepatic complications (including NASH)
B32	Ageing with HIV (including polypharmacy and frailty)
B33	Immune reconstitution disorders and immune reconstitution inflammatory syndrome
B34	Other non-communicable diseases
B35	Other ART complications and adverse reactions
B36	Substance abuse (including opioid use disorder)

Antiretroviral therapies in adults

B37	ART in acute infection
B38	ART in first- and second-line therapies
B39	ART in highly treatment-experienced people
B40	Management of late presenters
B41	Regimen simplification and switch studies
B42	Pharmacokinetics, pharmacodynamics, pharmacogenomics and therapeutic drug monitoring
B43	Drug interactions
B44	Antiretroviral drug resistance
B45	Long-acting agents and other drug delivery systems
B46	Adherence measurement
B47	Adherence promotion
B48	Ethical issues in clinical trials and treatment strategies
B49	New strategies (2DR, rapid start)

Other strategies and therapies (non-ART)

B50	Therapeutic vaccine trials
B51	Immune-based therapy trials
B52	Cure interventions
B53	Novel therapeutic approaches (including gene therapy)
B54	Pain and palliative medicine
B55	Nutrition
B56	Complementary and traditional medicines

Clinical issues specific to women

B57	Sex-specific issues of ART efficacy, adverse reactions and complications
B58	Pregnancy (clinical management issues and pharmacokinetics)
B59	Safe conception for serodiscordant couples
B60	Contraception
B61	Menopause
B62	Other sex- or gender-specific issues

Clinical issues specific to paediatric and adolescent HIV

B63	Diagnosis of HIV disease in paediatric and adolescent populations
B64	Pharmacokinetics, pharmacodynamics, pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations
B65	Drug formulations for infants and children
B66	Clinical trials in paediatric and adolescent populations
B67	ARV management strategies in paediatric and adolescent populations
B68	Cure strategies in paediatric and adolescent populations
B69	Adherence in paediatric and adolescent populations
B70	HIV complications and co-morbidities in paediatric and adolescent populations
B71	HIV-associated co-infections and malignancies in paediatric and adolescent populations
B72	Behavioural health outcomes in paediatric and adolescent populations
B73	Mental health and neurocognition in paediatric and adolescent populations
B74	HIV-exposed uninfected children
B75	Transition of adolescents into adult care

Clinical issues specific to key populations

B76	Clinical issues in men who have sex with men
B77	Clinical issues in people who use drugs
B78	Clinical issues in sex workers
B79	Clinical issues in transgender and non-binary populations
B80	Clinical issues in indigenous populations
B81	Clinical issues in migrant populations
B82	Clinical issues in other vulnerable populations